Intratumoral CXCL12 Gradients Contextualize Tumor Cell Invasion, Migration and Immune Suppression in Breast Cancer
Dimitra P. Anastasiadou,Nicole Couturier,Sakshi Goel,Dimitrios G. Argyris,Stepan Vodopyanov,Luis Rivera-Sanchez,Edgar Gonzalez,Jesse Kreger,Anthony Griffen,Abigail Kazakov,Joseph Burt,Natasha Recoder,Camille L. Duran,Allison S. Harney,Agathe Quesnel,Panagiota S. Filippou,Vasileios P. Lenis,Suryansh Shukla,David Entenberg,Aliona Zintiridou,Xiaoming Chen,Robert J. Eddy,Maja H. Oktay,John S. Condeelis,Nikolaos S. Karagiannis,Andrea Briceno,Hillary Guzik,Rotem Alon,Vera DesMarais,Giorgio Ioannou,Sacha Gnjatic,David M. Raynolds,Rodney Macedo,Ran Reshef,Hava Gil-Henn,Adam L. MacLean,Evanthia Roussos Torres,Lindsay M. LaFave,Gregoire Lauvau,George S. Karagiannis
DOI: https://doi.org/10.1101/2024.10.15.618571
2024-10-18
Abstract:Although the CXCL12/CXCR4 pathway has been prior investigated for its prometastatic and immuno-suppressive roles in the tumor microenvironment, evidence on the spatiotemporal regulation of these hallmarks has been lacking. Here, we demonstrate that CXCL12 forms a gradient specifically around cancer cell intravasation doorways, also known as Tumor Microenvironment of Metastasis (TMEM) doorways, thus facilitating the chemotactic translocation of prometastatic tumor cells expressing CXCR4 toward the perivascular TMEM doorways for subsequent entry into peripheral circulation. Furthermore, we demonstrate that the CXCL12-rich micro-environment around TMEM doorways may create immunosuppressive niches, whereby CD8+ T cells, despite being attracted to these regions, often exhibit reduced effector functions, limiting their efficacy. While the CXCL12/CXCR4 pathway can minimally influence the overall composition of immune cell populations, it biases the distribution of CD8+ T cells away from TMEM doorways, justifying its prior-established role as immunosuppressive factor for CD8+ T cells. Our research suggests that the complex interactions between CXCL12 and the various tumor and immune cell types contributes not only to the completion of the initial steps of the metastatic cascade, but also offers an immunological 'sanctuary' to prometastatic tumor cells homed around TMEM doorways. Overall, our study enhances our current understanding on the mechanisms, via which CXCL12 orchestrates tumor cell behavior and immune dynamics, potentially guiding future therapeutic strategies to combat breast cancer metastasis and improve anti-tumor immunity.
Cancer Biology